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Patients with diabetes mellitus are prone to 
infections. The reasons for this propensity are 
imperfectly defined. Ma et al. [1] in this issue 
suggest that defective macrophage function 
could be responsible. They studied F4/80-positive 
macrophages in spleen and peritoneal exudates 
of mice made them diabetic with streptozotocin. 
The macrophage number in the diabetic mice was 
reduced. Their immunogenic properties and 
nonopsonic phagocytosis to allogenic T cells were 
reduced. The antigen-presenting capacity of 
F4/80-positve macrophages from peritoneal 
exudates was also impaired. F4/80 is the cell 
surface target of a monoclonal antibody directed 
against mouse macrophages that was developed 
over 20 years ago by Austyn and Gordon [2]. The 
F4/80 molecule is expressed on macrophages, 
Kupffer cells, and microglial cells in the brain. The 
antigen has epidermal growth-factor-like domains 
connected to a C-terminal seven transmembrane 
region, placing it within the superfamily of G-
protein-coupled receptors. The F4/80 molecule 
has a role in antigen-specific tolerance induction; 
however, its ligands and signaling mechanisms 
are not yet defined [3]. A brief review of what 
these wondrous macrophages do is in order. 
Macrophages (Greek: “big eaters,” from makros 
“large” + phagein “eat”) are cells within the tissues 
that originate from monocytes (Fig. 1). Monocytes 
and macrophages are phagocytes, acting in both 
nonspecific defenses or “innate” immunity and 
specific acquired defenses. Macrophages 
phagocytose, that is engulf and then digest, 
cellular debris and pathogens either as stationary 
or mobile cells. Macrophages also serve to 
stimulate lymphocytes and other immune cells to 
respond to pathogens. When a monocyte enters 
damaged tissue through the endothelium of a 
blood vessel, a process known as the leukocyte 
adhesion cascade, the monocyte undergoes a 
series of interferon-gamma-mediated changes to 
become a macrophage. Monocytes are attracted 
to injury sites by chemical mediators through 
chemotaxis, triggered by a range of stimuli 
including damaged cells, pathogens, histamine 
released by mast cells and basophils, and 
chemokines and cytokines released by 
macrophages already at the site. Unlike short-
lived neutrophils, the life span of a macrophage 
ranges from months to years. 
Removing dead cell material is important in acute 
and chronic inflammation. Neutrophils and 
macrophages both express the cluster of 
differentiation molecule-31 (CD-31) also called 
platelet endothelial cell adhesion molecule 1. 
Neutrophils that are healthy can signal this state of 
affairs to the macrophage. However, if they are not 
and have phosphatidyl serine on their plasma 
membranes, they are scheduled for digestion. The 
removal of microparticles and necrotic tissue is to 
a greater extent handled by fixed macrophages, 
which will stay at strategic locations such as the 
lungs, liver, neural tissue, bone, spleen, and 
connective tissue. When a macrophage ingests a 
pathogen, the pathogen becomes trapped in a 
food vacuole, which then fuses with a lysosome. 
Within the lysosome, enzymes and toxic peroxides 
digest the invader. Macrophages can digest more 
than 100 bacteria before they finally die due to 
their own digestive compounds. 
Macrophages are versatile cells that play many 
roles. As scavengers, they rid the body of worn-out 
cells and other debris. As secretory cells, 
monocytes and macrophages are vital to the 
regulation of immune responses and the 
development of inflammation; they churn out an 
amazing array of powerful chemokines, cytokines, 
enzymes, complement proteins, and regulatory 
factors. At the same time, they carry receptors for 
lymphokines that allow them to be “activated” 
into single-minded pursuit of microbes and tumor 
cells. After digesting a pathogen, a macrophage 
will present the antigen of the pathogen to a 
corresponding helper T cell. The macrophage 
presents the antigen by integrating it into the cell 
membrane and displaying it attached to a major 
histocompatibility complex (MHC) class II 
molecule, indicating to other white blood cells 
that the macrophage is not a pathogen, despite 
having antigens on its surface. Eventually, the 
antigen presentation results in the production of 
antibodies that attach to the antigens of 
pathogens, making them easier for macrophages 
to adhere with their cell membrane and conduct 
phagocytosis. 
The antigen presentation on the surface of 
infected macrophages (in the context of MHC class 
II) in a lymph node stimulates type 1 helper T cells 
(TH1) to proliferate (mainly due to interleukin 12 
secretion from the macrophage). When a B cell 
Luft FC 
 
 
MDC Repository | http://edoc.mdc-berlin.de/9460/ 2 
 
in the lymph node recognizes the same 
unprocessed surface antigen on the bacterium 
with its surface-bound antibody, the antigen is 
endocytosed and processed. The processed 
antigen is then presented in MHCII on the surface 
of the B cell. The TH1 cells that have proliferated 
recognize the antigen MHCII complex (with 
costimulatory factors—CD40 and CD40L) via their 
T cell receptor and cause the B cell to produce 
antibodies that help opsonization of the antigen 
so that the bacteria can be better cleared by 
phagocytes. 
Macrophages provide yet another line of defense 
against tumor cells and body cells infected with 
fungus or parasites. Once a T cell has recognized 
its particular antigen on the surface of an aberrant 
cell, the T cell becomes an activated effector cell, 
releasing chemical mediators known as 
lymphokines that stimulate macrophages into a 
more aggressive form. These activated or “angry” 
macrophages can then engulf and digest affected 
cells much more readily. The angry macrophage 
does not generate a response specific for an 
antigen but attacks the cells present in the local 
area in which it was activated. 
We cannot live without our macrophages. 
However, questions remain whether or not they 
should be manipulated under certain 
circumstances. Oh et al. [4] studied the fractalkine 
receptor (CX3CR1) that is expressed on injured 
endothelial cells and serves as an attractant for 
macrophages. Inhibiting fractalkine ameliorated 
ischemia-reperfusion renal injury. Furthermore, 
poisoning macrophages with clodronate-laden 
liposomes can specifically deplete the cells. 
Macrophage depletion also ameliorated renal 
ischemia-reperfusion injury in this model. 
However, in a similar renal ischemia-reperfusion 
injury study, macrophage depletion led to 
inability of the injured kidney to conduct repair 
[5]. Repair mechanisms are absolutely essential for 
recovery. Thus, manipulating macrophages may 
give very diverse results depending upon the 
inflammatory milieu. Ma et al. observed different 
effects on splenic macrophages and peritoneal 
macrophages in their diabetic model [1]. The 
antigen-presenting capacity of peritoneal 
macrophages appeared particularly impaired. 
These findings may be related to differences in 
the microenvironment surrounding the cells. 
Whether or not the microvasculopathy 
accompanying diabetes is a manifestation of 
impaired repair remains to be seen. Suffice it to 
say, macrophages are unique immune cells whose 
effects extend beyond straightforward defensive 
activities. 
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►Fig.1. Two-stage activation of macrophages is shown. Resident and 
recruited macrophages require interferon gamma (IFNγ) to become 
primed. Local stimuli, microbial products, and dying cells trigger surface 
changes and cytokine production such as tumor necrosis factor, as well 
as reactive oxygen species. 
 
